Clinical Trial Finder

A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment

Study Purpose

This is a Phase 2, randomized two-armed, multi-site study of 170 patients with newly diagnosed glioblastoma multiforme. Patients will be randomized 1:1 to receive Keto Diet, or Standard Anti-Cancer Diet. All patients will receive standard of care treatment for their glioblastoma. The Keto Diet intervention will be for an 18-week period and conducted by trained research dietitians. Daily ketone and glucose levels will be recorded to monitor Keto Diet adherence. This two-armed randomized multi-site study aims to provide evidence to support the hypothesis that a Keto Diet vs.#46; Standard Anti-Cancer Diet improves overall survival in newly diagnosed glioblastoma multiforme patients who receive standard of care treatment.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

 No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

 Interventional
Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Adults 18 years or older.
  • - Newly diagnosed glioblastoma (Within 2 months of initial diagnosis by histopathology) - Not started standard of care chemotherapy and/or radiation therapy for glioblastoma.
  • - Karnofsky Performance Status (KPS) ≥ 70.
  • - Ability to read, write and understand either English OR Spanish.
  • - Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.

Exclusion Criteria:

  • - Patients with recurrent glioblastoma.
  • - Genetic disorders that affect lipid metabolism.
Including but not limited to pyruvate carboxylase deficiency, porphyria, primary carnitine deficiency, carnitine palmitoyltransferase I or II deficiency, carnitine translocase deficiency, beta-oxidation defects.
  • - Inability to wean steroids below 8mg dexamethasone / day or equivalent.
  • - Body Mass Index (BMI) < 21kg/m2, unless the site Principal Investigator deems safe.
  • - Currently pregnant or nursing.
  • - Patients receiving other experimental therapy Note: Off-label therapy use is permitted.
  • - Comorbidities that in the opinion of the investigator limit the patient's ability to complete the study.
  • - Food preferences incompatible with keto diet.
  • - Using a pacemaker, implantable cardiac defibrillator, neurostimulator, cochlear implants (removable hearing aids permitted), or other electronic medical equipment, unless the site Principal Investigator deems safe.
- Inability to participant in standard of care MRIs

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

 NCT05708352
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

 Phase 2
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

 Cedars-Sinai Medical Center
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

 Jethro Hu, MD
Principal Investigator Affiliation Cedars-Sinai Medical Center
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

 Other, NIH
Overall Status Recruiting
Countries United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

 Glioblastoma Multiforme
Arms & Interventions

Arms

Experimental: Keto-Diet

Intensive 18-week Keto Diet intervention.

Placebo Comparator: Standard Anti-Cancer Diet

Standard Anti-Cancer Diet with Dietitian support

Interventions

Behavioral: - Keto Diet

The experimental intervention includes a strict and controlled diet that manages daily macronutrient breakdown and increases the ratio of dietary fat relative to protein and carbohydrate consumption.

Behavioral: - Standard Anti-Cancer Diet

Dietitian sessions will utilize the American Institute for Cancer Research Food resources and will reference foods low in fats such as fruits, vegetables and whole grains, providing key micronutrients and phytonutrients. Sessions will also focus on dietary support to help decrease any treatment related symptoms.

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

Cedars-Sinai Medical Center, Los Angeles, California

Status

Recruiting

Address

Cedars-Sinai Medical Center

Los Angeles, California, 90048

Site Contact

Clinical Trial Recruitment Navigator

[email protected]

310-423-2133

University of California, San Francisco, San Francisco, California

Status

Recruiting

Address

University of California, San Francisco

San Francisco, California, 94143

Site Contact

Nicholas Butowski, MD

[email protected]

415-353-2302

Santa Monica, California

Status

Recruiting

Address

Pacific Neuroscience Institute / Saint John's Cancer Institute

Santa Monica, California, 90404

Site Contact

Akanksha Sharma, MD

[email protected]

310-829-8265

Duke University, Durham, North Carolina

Status

Not yet recruiting

Address

Duke University

Durham, North Carolina, 27705

Site Contact

Katherine Peters, MD, PhD

[email protected]

919-684-5301

Medical College of Wisconsin, Milwaukee, Wisconsin

Status

Not yet recruiting

Address

Medical College of Wisconsin

Milwaukee, Wisconsin, 53226

Site Contact

Ekokobe Fonkem, DO

[email protected]

3104232133

Powered By

Stay Informed & Connected